echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Shufang Medicine assists Xiangya Second Hospital in launching the first 5D smart diagnosis and treatment center for pulmonary hypertension in China

    Shufang Medicine assists Xiangya Second Hospital in launching the first 5D smart diagnosis and treatment center for pulmonary hypertension in China

    • Last Update: 2021-10-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Shanghai September 26, 2021/PRNewswire/ - September 25, at the 8th Xiaoxiang Pulmonary Vascular Disease Forum and the 2021 Hunan Provincial Health Management Association Pulmonary Vascular Disease Health Management Professional Committee Academic Annual Meeting, Central South University, Hunan Professor Li Jiang, director of the Pulmonary and Vascular Disease Sub-specialty Department of the Department of Cardiology, Ya Second Hospital, officially announced that, leveraging the advantages of digital tools in remote, real-time, automation, and intelligence, the Second Xiangya Hospital officially launched the first domestic pulmonary hypertension "5D smart diagnosis and treatment center
    .
    "

    Li Jiang introduced that the "5D" of the "5D Smart Diagnosis and Treatment Center" refers to doctor network, data mining, disease management, smart wearable (Device link), and digital empowerment (Data plus).
    An innovative diagnosis and treatment model that combines five dimensions

    .

    "In the era of pulmonary hypertension diagnosis and treatment 1.
    0, due to the scattered patient data, not only the workload of medical staff is large, scientific research is difficult, but it is also difficult to improve the compliance of patients with treatment

    .
    " Li Jiang said that the 5D smart diagnosis and treatment tool was launched to cooperate with doctors' clinical management to assist doctors.
    Digital batch management of patient information, regular follow-up, disease monitoring, upper and lower consultations, and treatment effect evaluation are important measures for deep linking with doctors and patients and improving the quality of clinical and scientific research

    .

    As a supporter of the project, Shufang Pharmaceutical, an innovative company focusing on the development and commercialization of new drugs for rare diseases, and the left-hand doctor, a leading medical artificial intelligence company, jointly assisted the Second Xiangya Hospital to build a diagnosis and treatment covering pulmonary hypertension before, during and after diagnosis.
    The entire process, scientific research data collection and management, and regional specific disease diagnosis and treatment collaboration and other multi-scenario AI service platforms, together usher in the 2.
    0 era of smart diagnosis and treatment of pulmonary hypertension

    .

    The pictures are: Zhang Chao, founder and CEO of Left Hand Doctor, Li Jiang, Director of Pulmonary and Vascular Disease Subspecialty, Department of Cardiology, Second Xiangya Hospital of Central South University, Yan Zhiyu, Chairman of Shufang Medicine, Xu Qing, Head of Innovative Business Development, Li Dongxue, Product Manager, and Xiangya, Central South University Luo Jun, Attending Physician, Department of Cardiology, Ya Second Hospital

    AI empowers a new model of doctor-patient connection

    Pulmonary hypertension is a rare and fatal cardiopulmonary vascular disease.
    Because of its severe disabling and lethality, it is also called "cancer in the cardiovascular field".
    The incidence and prevalence are about 5-10 per million people.
    Years and 15-60/million, if you do not intervene as soon as possible, along with the increase in pulmonary artery pressure, patients often have abnormal pulmonary vascular structure and/or function, which will increase pulmonary vascular pressure and resistance and continue to increase cardiac load

    .
    As the disease progresses, the patient will experience hypertrophy and enlargement of the right ventricle, eventually progressive right heart failure, and even premature death

    .

    Clinical data shows that the current diagnosis and treatment of patients with pulmonary hypertension has yet to be improved
    .
    In the "White Paper on the Survival Status of Patients with Pulmonary Hypertension in China" released in April 2021, more than half of the respondents may not meet the initial treatment standard or return after discharge due to factors such as disease awareness, access to treatment, and medical burden.
    Irregularities, resulting in worsening of the disease and poor prognosis, and standardized diagnosis and treatment of patients urgently need to be improved

    .

    "As a standardized diagnosis and treatment center for pulmonary hypertension in Hunan Province, the birth of the 5D smart diagnosis and treatment model for pulmonary hypertension will greatly improve this dilemma
    .
    " Professor Li Jiang said that this achievement has changed the focus of medical care from a single "seeing diagnosis and treatment" to "multiple methods".
    The intelligent model of "collaboration, precise treatment, and long-term management" can not only effectively deepen the doctor-patient connection and strengthen disease management and control, but also has a milestone significance in advancing clinical scientific research

    .

    Li Jiang, Director, Pulmonary and Vascular Disease Subspecialty, Department of Cardiology, The Second Xiangya Hospital, Central South University

    The advantages of the 5D smart diagnosis and treatment model are first reflected in the efficient management and information transmission of patients
    .
    In the display picture of Phase I of the system, the 5D Smart Diagnosis and Treatment Center gives full play to the advantages of AI in efficiently processing complex medical language

    .
    Patients can not only receive professional medical services such as medical advice, disease science popularization, medication guidance, smart follow-up, and review reminders, but also initiate self-assessment, online consultation, and drug purchase requests

    .
    At the same time, the information input by the patient is structured and analyzed by the AI ​​system.
    On the one hand, follow-up data statistics and personalized follow-up plans will be automatically generated to the PC management terminal for the hospital to store and analyze data; on the other hand, the management plan will be generated intelligently , Follow-up plan and early warning system to the doctor’s mobile phone, providing a vertical path for doctor-patient communication

    .
    While improving patient compliance with treatment, doctors can more efficiently and accurately manage the course of disease and medication management, thereby improving the long-term quality of life of patients

    .

    "As a technical partner of the project, we are looking forward to using this milestone product to promote the establishment of an AI doctor-driven and efficient doctor-patient interaction model in China, breaking down multiple barriers such as time and space for patients with rare diseases, and allowing them to enjoy high-quality products.
    , Efficient medical services

    .
    ” said Zhang Chao, founder and CEO of Left Hand Doctor

    .

    Zhang Chao, founder and CEO of Left Hand Doctor

    AI technology helps clinical research on rare diseases

    Another bright spot that has attracted attention is the promotion of the 5D smart diagnosis and treatment center in clinical research
    .
    The data accumulated by the interaction between doctors and patients can supplement the lack of epidemiological data, improve the scientific basis of "orphan drugs", and provide quantitative data support for medical research

    .

    "AI technology allows us to see more possibilities
    .
    " Yan Zhiyu, chairman of Shufang Pharmaceutical, said that the greatest significance of the 5D smart diagnosis and treatment model lies in the ability to effectively overcome the obstacles to medical treatment in the real world caused by the wide area and uneven medical resources.
    Dispersed and lagging patient data are transformed into online standardized and real-time clinical data.
    The establishment of a personalized management plan around each patient not only provides a strong guarantee for the treatment and rehabilitation of patients, but also speeds up the treatment and recovery of medical institutions in rare cases.
    Progress in research on disease medicine

    .

    Yan Zhiyu, co-founder, chairman and CEO of Shufang Pharmaceutical

    "Using artificial intelligence and digital medical technology to empower disease diagnosis and treatment and clinical research is the direction we have been practicing
    .
    " Yan Zhiyu said, "In the future, we will continue to strengthen the doctor-patient link and help the '5D smart diagnosis and treatment center' model in more Applications in the field of rare diseases

    .
    Although this road is not smooth, a lot of feedback from doctors and patients tells us that this road is worth going on

    .
    "

    Source: Shufang Medicine

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.